New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literature.

[1]  A. Lazarus,et al.  CD20+ B-cell depletion therapy suppresses murine CD8+ T-cell-mediated immune thrombocytopenia. , 2016, Blood.

[2]  U. Maggiore,et al.  Clinical usefulness of autoantibodies to M-type phospholipase A2 receptor (PLA2R) for monitoring disease activity in idiopathic membranous nephropathy (IMN). , 2016, Autoimmunity reviews.

[3]  D. Bogdanos,et al.  Systemic sclerosis: New evidence re-enforces the role of B cells. , 2016, Autoimmunity reviews.

[4]  Rakeshchandra R. Meka,et al.  IL-27-induced modulation of autoimmunity and its therapeutic potential. , 2015, Autoimmunity reviews.

[5]  S. Baldovino,et al.  A 4-year observation in lupus nephritis patients treated with an intensified B-lymphocyte depletion without immunosuppressive maintenance treatment-Clinical response compared to literature and immunological re-assessment. , 2015, Autoimmunity reviews.

[6]  L. Mouthon,et al.  Implication of B lymphocytes in the pathogenesis of ANCA-associated vasculitides. , 2015, Autoimmunity reviews.

[7]  A. Antonelli,et al.  Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature. , 2015, Autoimmunity reviews.

[8]  C. Tinelli,et al.  Efficacy of low-dose rituximab for the treatment of mixed cryoglobulinemia vasculitis: Phase II clinical trial and systematic review. , 2015, Autoimmunity reviews.

[9]  G. Ruoppolo,et al.  Microscopic polyangiitis: Advances in diagnostic and therapeutic approaches. , 2015, Autoimmunity Reviews.

[10]  A. Liston,et al.  Humoral autoimmunity: a failure of regulatory T cells? , 2015, Autoimmunity reviews.

[11]  G. Remuzzi,et al.  Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. , 2015, Journal of the American Society of Nephrology : JASN.

[12]  M. Gershwin,et al.  IL-35 and Autoimmunity: a Comprehensive Perspective , 2015, Clinical Reviews in Allergy & Immunology.

[13]  F. Fervenza,et al.  Glomerular disease in 2014: Advances in basic science and translational medicine , 2015, Nature Reviews Nephrology.

[14]  G. Lambeau,et al.  Prediction of membranous nephropathy recurrence after transplantation by monitoring of anti-PLA2R1 (M-type phospholipase A2 receptor) autoantibodies: a case series of 15 patients. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[15]  G. Remuzzi,et al.  Rituximab in Primary Membranous Nephropathy: First-Line Therapy, Why Not? , 2014, Nephron Clinical Practice.

[16]  U. Panzer,et al.  M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. , 2014, Clinical journal of the American Society of Nephrology : CJASN.

[17]  M. Khamashta,et al.  The efficacy of novel B cell biologics as the future of SLE treatment: a review. , 2014, Autoimmunity reviews.

[18]  U. Panzer,et al.  PLA2R Antibody Levels and Clinical Outcome in Patients with Membranous Nephropathy and Non-Nephrotic Range Proteinuria under Treatment with Inhibitors of the Renin-Angiotensin System , 2014, PloS one.

[19]  U. Panzer,et al.  Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy. , 2014, Journal of the American Society of Nephrology : JASN.

[20]  A. Segarra-Medrano,et al.  Prevalence, diagnostic value and clinical characteristics associated with the presence of circulating levels and renal deposits of antibodies against the M-type phospholipase A2 receptor in idiopathic membranous nephropathy. , 2014, Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia.

[21]  P. Niaudet,et al.  Allo-immune membranous nephropathy and recombinant aryl sulfatase replacement therapy: a need for tolerance induction therapy. , 2014, Journal of the American Society of Nephrology : JASN.

[22]  Amit Bar-Or,et al.  IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases , 2014, Nature.

[23]  Nora Hornig,et al.  Differential diagnosis of membranous nephropathy with autoantibodies to phospholipase A2 receptor 1. , 2014, Autoimmunity reviews.

[24]  D. Roccatello,et al.  Rituximab-based novel strategies for the treatment of immune-mediated glomerular diseases. , 2013, Autoimmunity reviews.

[25]  A. Pani.  Standard immunosuppressive therapy of immune-mediated glomerular diseases. , 2013, Autoimmunity reviews.

[26]  P. Walker,et al.  Phospholipase A2 Receptor (PLA2R) Staining Is Useful in the Determination of De Novo Versus Recurrent Membranous Glomerulopathy , 2013, Transplantation.

[27]  D. Adu,et al.  Immunosuppression for progressive membranous nephropathy: a UK randomised controlled trial , 2013, The Lancet.

[28]  C. Ponticelli.  What is the role of rituximab in idiopathic membranous nephropathy? , 2013, Expert review of clinical immunology.

[29]  J. Wetzels,et al.  Antiphospholipase A2 receptor antibody titer and subclass in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[30]  G. Remuzzi,et al.  Rituximab in idiopathic membranous nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[31]  F. Fervenza,et al.  Rituximab: emerging treatment strategies of immune-mediated glomerular disease , 2012, Expert review of clinical immunology.

[32]  R. Nair,et al.  Very Early Recurrence of Anti‐Phospholipase A2 Receptor‐Positive Membranous Nephropathy After Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[33]  J. Wetzels,et al.  anti-Pla 2 r antibodies in membranous nephropathy: ready for routine clinical practice? , 2012 .

[34]  D. Roccatello,et al.  Treatment with rituximab in patients with mixed cryoglobulinemia syndrome: results of multicenter cohort study and review of the literature. , 2011, Autoimmunity reviews.

[35]  E. Rondeau,et al.  Autoantibodies Specific for the Phospholipase A2 Receptor in Recurrent and De Novo Membranous Nephropathy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  David M. Beck,et al.  Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. , 2011, Journal of the American Society of Nephrology : JASN.

[37]  S. Baldovino,et al.  Long-Term Effects of Rituximab Added to Cyclophosphamide in Refractory Patients with Vasculitis , 2011, American Journal of Nephrology.

[38]  G. Remuzzi,et al.  Efficacy and Safety of Rituximab Second-Line Therapy for Membranous Nephropathy: A Prospective, Matched-Cohort Study , 2011, American Journal of Nephrology.

[39]  Spencer T. Martin,et al.  Induction immunosuppressive therapies in renal transplantation. , 2011, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[40]  F. Cosio,et al.  Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[41]  R. Stahl,et al.  PLA2R autoantibodies and recurrent membranous nephropathy after transplantation. , 2010, The New England journal of medicine.

[42]  R. Glassock.  The pathogenesis of idiopathic membranous nephropathy: a 50-year odyssey. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[43]  G. Fernández-Juárez,et al.  Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. , 2010, Journal of the American Society of Nephrology : JASN.

[44]  M. Segelmark,et al.  Autoimmune kidney diseases. , 2010, Autoimmunity reviews.

[45]  R. Glassock.  Human idiopathic membranous nephropathy--a mystery solved? , 2009, The New England journal of medicine.

[46]  J. Levy,et al.  Rituximab is an effective treatment for lupus nephritis and allows a reduction in maintenance steroids. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[47]  David M. Beck,et al.  M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. , 2009, The New England journal of medicine.

[48]  M. Praga,et al.  Successful treatment of membranous glomerulonephritis with rituximab in calcineurin inhibitor-dependent patients. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[49]  A. Kshirsagar,et al.  Rituximab therapy for membranous nephropathy: a systematic review. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[50]  D. Bernard,et al.  The M‐type receptor PLA2R regulates senescence through the p53 pathway , 2009, EMBO reports.

[51]  G. Remuzzi,et al.  Rituximab for membranous nephropathy and immune disease: less might be enough , 2009, Nature Clinical Practice Nephrology.

[52]  G. Remuzzi,et al.  Effects of rituximab on morphofunctional abnormalities of membranous glomerulopathy. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[53]  U. Specks,et al.  Idiopathic membranous nephropathy: diagnosis and treatment. , 2008, Clinical journal of the American Society of Nephrology : CJASN.

[54]  K. Boyd,et al.  The inhibitory cytokine IL-35 contributes to regulatory T-cell function , 2007, Nature.

[55]  G. Remuzzi,et al.  Titrating rituximab to circulating B cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[56]  J. Phillips,et al.  Nephrotic Syndrome Complicating α-Glucosidase Replacement Therapy for Pompe Disease , 2004, Pediatrics.

[57]  A. Komatsuda,et al.  Distribution of glomerular IgG subclass deposits in malignancy-associated membranous nephropathy. , 2004, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[58]  H. Coovadia,et al.  Hepatitis B Virus-Associated Nephropathy , 2004, American Journal of Nephrology.

[59]  R. Glassock.  Diagnosis and natural course of membranous nephropathy. , 2003, Seminars in nephrology.

[60]  G. Remuzzi,et al.  Rituximab in idiopathic membranous nephropathy: a one-year prospective study. , 2003, Journal of the American Society of Nephrology : JASN.

[61]  G. Remuzzi,et al.  Rituximab for idiopathic membranous nephropathy , 2002, The Lancet.

[62]  J. Haymann,et al.  Antenatal membranous glomerulonephritis due to anti-neutral endopeptidase antibodies. , 2002, The New England journal of medicine.

[63]  R. Aalberse,et al.  IgG4 breaking the rules , 2002, Immunology.

[64]  G. D'Amico,et al.  Urinary excretion of IgG and alpha(1)-microglobulin predicts clinical course better than extent of proteinuria in membranous nephropathy. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[65]  L. Hebert,et al.  Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial. , 2001, Kidney international.

[66]  R. Würzner,et al.  Glomerular deposition of mannose-binding lectin in human glomerulonephritis. , 1999, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[67]  C. Ponticelli,et al.  Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications. , 1997, Kidney international.

[68]  J. Donohoe,et al.  Clinical and histopathologic findings in adults with the nephrotic syndrome , 1990, Irish journal of medical science.

[69]  R. Aalberse,et al.  Inhibition of complement activation by IgG4 antibodies. , 1986, Clinical and experimental immunology.

[70]  J. Lieske,et al.  Low- and high-molecular-weight urinary proteins as predictors of response to rituximab in patients with membranous nephropathy: a prospective study. , 2013, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[71]  E. Gutiérrez,et al.  Spontaneous remission of nephrotic syndrome in membranous nephropathy with chronic renal impairment. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[72]  D. Cattran.  Membranous nephropathy: quo vadis? , 2002, Kidney international.

[73]  Y. Pei,et al.  Predicting progression in membranous glomerulonephritis. , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.